In total, 11 lots of three different products have been recalled because of silicone found in retained samples.
Exela Pharma Sciences is recalling several products because of the presence of silicone found in retained samples. Injection with the presence of particulates such as silicone can cause irritation and swelling. If it reaches blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain, which can cause stroke and even lead to death. Exela has not received any reports of adverse events related to this recall.
The products recalled include:
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More